

Bacillus Calmette-Guérin monotherapy in patients with High risk Non-Muscle Invasive Bladder Cancer

(EUDRACT Number 2017- 004540-37): MITOBCG preliminary results

De Nunzio C. ¹, Nacchia A. ¹, Lombardo R¹, Simone G. ², Leonardo C. ³, Pastore A. ³, Tubaro A. ¹


¹Sapienza University of Rome, Sant'Andrea Hospital, Dept. of Urology, Rome, Italy,
²IFO, Istituto Nazionale Tumori Regina Elena Hospital, Dept. of Urology, Rome, Italy,
³Sapienza University of Rome, Umberto I Hospital, Dept. of Urology, Rome, Italy
⁴Department of Urology, ICOT Latina, Italy

OBJECTIVE

✓ To evaluate efficacy and safety of sequential Mitomycin and Bacillus Calmette-Guérin treatment versus Bacillus Calmette-Guérin monotherapy in patients with High risk Non-Muscle Invasive Bladder Cancer

MATERIAL & METHODS

Inclusion Criteria	Exclusion Criteria
<ul style="list-style-type: none"> •Patients with high risk non muscle invasive bladder cancer •High risk of recurrence (EORTC risk score ≥ 10) •Males •Signature of Informed Consent •Ability of consent 	<ul style="list-style-type: none"> •Low Risk Non-Muscle Invasive Bladder Cancer •Muscle Invasive Bladder Cancer •Concomitant Urothelial Bladder Cancer in the Upper-Urinary Tract •Previous bladder or prostate surgery •Prostate or bladder radiotherapy •Urinary tract infection •Chronic urinary retention or indwelling catheters •Neurological patients •Previous BCG infections •Previous or current chemotherapy for other kind of cancers •Patients older than 75 •WHO performance status 3-4 •Residual tumour on re-TURB



	Monotherapy BCG Group	Combination Therapy Group	p
Patients	21 (58%)	15 (42%)	
IPSS	9 (IQR 4/11)	11 (IQR 8/15)	0,21
sIPSS	5 (IQR 2/9)	8 (IQR 2/10)	0,27
vIPSS	2 (IQR 1/5)	5 (IQR 1/6)	0,31
NIH-CPSI total	8 (IQR 6/11)	8 (IQR 6/19)	0,13
NIH-CPSI pain	2 (IQR 1/3)	1 (IQR 0/7)	0,12
NIH-CPSI micturition	3 (IQR 1/6)	4 (IQR 1/8)	0,74
NIH-CPSI QoL	3 (IQR 2/4)	5 (IQR 2/6)	0,14
PUF total	15 (IQR 10/21)	15 (IQR 11/21)	0,91
PUF SS	9 (IQR 6/11)	9 (IQR 7/10)	0,89
PUF BS	6 (IQR 5/8)	6 (IQR 5/8)	0,86
AEs	3 (50%)	3 (50%)	0,92
Grade I	2 (67%)	3 (100%)	0,57
Grade II	0	0	
Grade III	1 (33%)	0	0,54
Grade IV	0	0	
Grade V	0	0	

Conclusions

- Protocol study started on March 2019
- Enrollment will continue till 200 patients are included
- Preliminary results of our experience (MITOBCG study) support that sequential combination therapy with Mytomycin and BCG is a safety treatment in high risk non muscle invasive bladder cancer.

References

1.EAU - NMIBC Oncology Guidelines, M. Babjuk (Chair), A. Böhle, M. Burger, E. Compérat, E. Kaasinen, J. Palou, B.W.G. van Rhijn, M. Rouprêt, S. Shariat, R. Sylvester, R. Zigeuner, Guidelines Associates: O. Capoun, D. Cohen, V. Hernández, V. Soukup. Eur Urol 2013 2. *Solsona et al.* Sequential Combination of Mitomycin Plus Bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in Patients with Non Muscle Invasive Bladder Cancer in Intermediate- and High- Risk Patients: Final Outcome of CUETO 93009, a Randomized Prospective Trial; Eur. Urol. 2015 3. *Jianfeng et al.* Combination of Intravesical Chemotherapy and Bacillus Calmette-Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer; Medicine, 2016 4. *Y. Lan et al* Comparison of the combination therapy of bacillus Calmette-Guérin and mitomycin C with the monotherapy for non-muscle-invasive bladder cancer: a meta-analysis. Neoplasma, 20165. *Kaasinen et al* Seventeen-year follow up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder. Scandinavian Journal of Urology, 2016